Enabling critical testing needs in clinical microbiology: innovative, random-access molecular diagnostic solutions to address pandemic and post-pandemic needs
Monday, July 12, 2021
11. Other, 2-hour Integrated Symposium
11c. Other
•
2707
•
4:15 PM
>
6:15 PM
•
Enabling critical testing needs in clinical microbiology: innovative, random-access molecular diagnostic solutions to address pandemic and post-pandemic needs
•
13. Integrated sessions - 1
11c. Other
As the COVID-19 pandemic has demonstrated, clinical microbiology laboratories need to be able to detect both known and novel pathogens whilst efficiently managing both routine and pandemic testing volumes. The adoption of easy to use, fully automated systems with true random access allows laboratories to rapidly adjust to changing diagnostic needs while maintaining routine testing. Such diagnostic platforms also need to provide rapid results to inform critical patient care decisions and public health interventions. Platforms which feature open channel capability offer additional value as they can be utilised for testing novel pathogenic threats, offering a future proof solution. This session will provide four distinct international insights on the topic of random access molecular diagnostic platforms in clinical microbiology
4:15 PM
•
2707-1
•
Expedite diagnoses: benefits of random access capabilities. A laboratory perspective
>
N.
Nadine
LÜBKE (Dusseldorf)
4:40 PM
•
2707-2
•
Seasonal adaption: testing options to cope with changing seasonal testing priorities. A laboratory perspective
>
M.
Michiel
VAN RIJN (Rotterdam)
5:05 PM
•
2707-3
•
Allocate resources: impact of flexible platforms in managing large patient populations. A clinician’s perspective
>
R.
Robert
STRASSL (Vienna)
5:30 PM
•
2707-4
•
Testing choice: use of automated molecular HPV assays in cervical cancer screening programs. A virologist’s perspective
>
A.
Anja
ŠTERBENC (Ljubljana)
5:55 PM
•
2707-5
•
Panel discussion – Q&A
|